血管腔内时代开放腹主动脉瘤修复的当代适应证
单中心2004至2019年370例开放腹主动脉瘤修复的回顾性队列研究显示,71.6%患者存在至少一项EVAR解剖禁忌,围手术期主要并发症率18.1%、30天死亡率3.0%;因患者或术者偏好行开放修复者并发症更少、住院更短、15年死亡风险更低。
要点
- 开放修复最常见解剖禁忌为近端瘤颈短(51.6%)、远端锚定区不足(19.2%)和入路血管不佳(15.7%)。
- 无单一解剖因素可预测开放修复围手术期并发症。
- 患者或术者偏好组围手术期主要并发症8.2% vs 解剖或全身禁忌组20.1%(P = .034)。
核心结论
- 在不符合EVAR说明书使用标准的患者中,无单一解剖禁忌是开放修复预后更差的标志。
- 同时适合两种修复方式但因患者或术者偏好选择开放修复者,30天死亡率和并发症率极低,长期生存优于因解剖或全身禁忌行开放修复者。
研究设计与样本
- 回顾性队列研究,纳入单中心2004至2019年所有开放腹主动脉瘤修复患者370例。
- 通过术前CT和手术记录确定开放修复指征,分为解剖禁忌、全身因素(结缔组织病、造影剂禁忌)及患者或术者偏好三组。
- 比较各组围手术期和长期结局。
主要发现
- 71.6%(265/370)存在至少一项EVAR解剖禁忌,36%存在两项或以上禁忌。
- 最常见解剖禁忌为近端瘤颈短(51.6%)、远端锚定区不足(19.2%)、入路血管不佳(15.7%)。
- 围手术期主要并发症率18.1%,30天死亡率3.0%,未发现单一解剖因素预测围手术期并发症。
- 患者或术者偏好组61例(16.5%),较解剖和/或全身禁忌组更年轻、冠心病和慢性阻塞性肺疾病发生率更低、需肾上阻断更少。
- 患者或术者偏好组围手术期主要并发症8.2% vs 解剖和/或全身禁忌组20.1%(P = .034),住院6天 vs 8天(P < .001),30天死亡为零。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite the emergence of endovascular aneurysm repair (EVAR) as the most common approach to abdominal aortic aneurysm repair, open aneurysm repair (OAR) remains an important option. This study seeks to define the indications for OAR in the EVAR era and how these indicatioxns effect outcomes. METHODS: A retrospective cohort study was performed of all OAR at a single institution from 2004 to 2019. Preoperative computed tomography scans and operative records were assessed to determine the indication for OAR. These reasons were categorized into anatomical contraindications, systemic factors (connective tissue disorders, contraindication to contrast dye), and patient or surgeon preference (patients who were candidates for both EVAR and OAR). Perioperative and long-term outcomes were compared between the groups. RESULTS: We included 370 patients in the analysis; 71.6% (265/370) had at least one anatomic contraindication to EVAR and 36% had two or more contraindications. The most common anatomic contraindications were short aortic neck length (51.6%), inadequate distal seal zone (19.2%), and inadequate access vessels (15.7%). The major perioperative complication rate was 18.1% and the 30-day mortality was 3.0%. No single anatomic factor was identified as a predictor of perioperative complications. Sixty-one patients (16.5%) underwent OAR based on patient or surgeon preference; these patients were younger, had lower incidences of coronary artery disease and chronic obstructive pulmonary disease, and were less likely to require suprarenal cross-clamping compared with patients who had anatomic and/or systemic contraindications to EVAR. The patient or surgeon preference group had a lower incidence of perioperative major complications (8.2% vs 20.1%; P = .034), shorter length of stay (6 days vs 8 days; P < .001) and no 30-day mortalities. The multivariable adjusted risk for 15-year mortality was lower for patient or surgeon preference patients (adjusted hazard ratio, 0.44; 95% confidence interval, 0.24-0.80; P = .007) compared with those anatomic or systemic contraindications. CONCLUSIONS: Within a population of patients who did not meet instruction for use criteria for EVAR, no single anatomic contraindication was a marker for worse outcomes with OAR. Patients who were candidates for both aortic repair approaches but elected to undergo OAR owing to patient or surgeon preference have very low 30-day mortality and morbidity, and superior long-term survival rates compared with those patients who underwent OAR owing to anatomic and/or systemic contraindications to EVAR.
引用
- Soo Hoo AJ, Fitzgibbon JJ, Hussain MA, et al. Contemporary indications for open abdominal aortic aneurysm repair in the endovascular era. J Vasc Surg. 2022. PMID: 35367568. doi:10.1016/j.jvs.2022.03.866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。